Bharat Biotech International Ltd on Tuesday announced the launch of Hillchol, a novel single-strain oral cholera vaccine.
A press release from the vaccine maker said Hillchol (BBV131) was developed by Bharat Biotech under licence from Hilleman Laboratories (funded by Merck USA and Wellcome Trust) to combat Cholera.
Global demand for Oral Cholera Vaccines (OCVs) exceeds 100 million doses annually, making them crucial for cholera control. Globally, there is a shortage of OCVs as there is only one manufacturer.
BBIL has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of Hillchol, it further said.
A multi-stage, clinical evolution process, culminating in a Phase 3 study confirmed the vaccine safety, immunogenicity and non-inferiority to existing OCVs, establishing its potential for white spirit, and public health use.
The vaccine, a single dose respule, is administered orally on day 0 and 14 and is suitable for individuals older than one year.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Featured Video Of The Day
Police File FIR After A 35-Feet Shivaji Statue Collapsed In Maharashtra
"Critical Shortage" Of Cholera Vaccine, Says WHO, Calls for Production Boost Cholera Vaccine Shortage Forces Move To Temporary One-Dose Strategy: WHO In World's Worst Cholera Outbreak, Vaccine Talks Hang In The Balance "What Is This 'Fairness'?" Top Court To Probe Agencies In Liquor Policy Case 'Just Because Woman Is Educated...': Top Court's Rap As K Kavitha Gets Bail Scientist Claims He's Found "Perfect Hiding Place" For Missing MH370 Flight Gaza Hostage Rescued After 10 Months "In Complex Operation", Says Israel "Truth Must Come Out...": Kerala Actor Accused Of Sex Assault Claims Blackmail Namibian Male Cheetah Dies At Kuno National Park In Madhya Pradesh Track Latest News Live on NDTV.com and get news updates from India and around the world.